Antivirals

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Retrieved on: 
Thursday, October 8, 2020

We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.

Key Points: 
  • We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.
  • Emergent is one of four companies providing hyperimmune globulin products for the trial, which plans to enroll approximately 500 patients across U.S. and international clinical trial sites.
  • The main goal of the trial is to compare the health status of participants treated with hyperimmune globulin plus remdesivir with participants treated with a placebo plus remdesivir.
  • Using its established hyperimmune platforms, Emergent is developing two investigational plasma-based treatments - COVID-19 Human Immune Globulin (COVID-HIG) and COVID-Equine Immune Globulin (COVID-EIG).

iownit and Sudrania Deliver a Digital Solution with Straight Through Processing for Private Investments

Retrieved on: 
Thursday, October 8, 2020

Through their partnership Sudrania and iownit will enable asset managers to expand access to private investment products.

Key Points: 
  • Through their partnership Sudrania and iownit will enable asset managers to expand access to private investment products.
  • Through their partnership Sudrania and iownit will enable asset managers to expand access to private products, seamlessly create investment vehicles, and provide their clients with a simplified investment process.
  • At iownit, we work tirelessly to enable simplified, fully digital investment execution and management experiences in the private securities market.
  • Mr. Sudrania added, "The iownit digital platform expands the seamless experience, by introducing fund managers to potential investors."

Global Hepatitis B Market Spotlight Report 2020: Aligos Deals Separately Target COVID-19, Hepatitis B - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020

The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.
  • Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, interferon receptor, interferon-alpha, and the immune system.
  • China leads in terms of the number of hepatitis B clinical trials globally, while Germany leads the major European markets.
  • GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for hepatitis B, followed by Gilead.

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)

Retrieved on: 
Thursday, October 8, 2020

Gilead Sciences (Nasdaq: GILD) and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU).

Key Points: 
  • Gilead Sciences (Nasdaq: GILD) and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU).
  • The JPA enables participating countries in the EU and the European Economic Area (EEA) and the UK to purchase Veklury for both real-time demand and stockpiling needs, coordinated by the European Commission.
  • The agreement covers purchases of Veklury over the next six months and has the option to be extended.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19

Retrieved on: 
Friday, October 2, 2020

The request for the pre-IND meeting follows the FDA guidance issued in May 2020, COVID-19 Public Health Emergency: General Considerations for Pre-IND Meeting Requests for COVID-19 Related Drugs and Biological Products.

Key Points: 
  • The request for the pre-IND meeting follows the FDA guidance issued in May 2020, COVID-19 Public Health Emergency: General Considerations for Pre-IND Meeting Requests for COVID-19 Related Drugs and Biological Products.
  • Confirmation of the meeting being granted by FDA, with return of written responses, has been received.
  • Extensive pre-clinical research, nearing completion, conducted at independent laboratories reinforces the antiviral potential of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19.
  • Numerous hospitals and provider networks domestically and abroad have expressed a strong interest in participating in the Brilacidin for COVID-19 clinical trial.

Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States

Retrieved on: 
Thursday, October 1, 2020

Starting on October 1, Gilead will be responsible for distributing Veklury in the United States upon conclusion of the previous distribution agreement with the U.S. Federal government.

Key Points: 
  • Starting on October 1, Gilead will be responsible for distributing Veklury in the United States upon conclusion of the previous distribution agreement with the U.S. Federal government.
  • Hospitals will control the quantity of Veklury that they order, enabling them to have ample, predictable supply of Veklury in advance of any anticipated increase in COVID-19 incidence.
  • In addition, there is also the risk that Gilead may be unable to effectively manage the global supply and distribution of Veklury.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

Retrieved on: 
Wednesday, September 30, 2020

ViralClear to contribute its oral antiviral merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19.

Key Points: 
  • ViralClear to contribute its oral antiviral merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19.
  • ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.
  • The agreement between ViralClear Pharmaceuticals, Inc. (Parent company BioSig Technologies, Inc. Nasdaq: BSGM), and Sorrento Therapeutics will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.
  • Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 [email protected] 203-409-5444, x133

Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19

Retrieved on: 
Wednesday, September 30, 2020

ViralClear to contribute its oral antiviral Merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19.

Key Points: 
  • ViralClear to contribute its oral antiviral Merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19.
  • WESTPORT, Conn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.
  • The agreement between ViralClear Pharmaceuticals, Inc. (Parent company BioSig Technologies, Inc. Nasdaq:BSGM) and Sorrento Therapeutics will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.
  • Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
    G-MAB, COVI-GUARDTM, COVI-SHIELD, COVIDTRAP, T-VIVA-19, COVI-MAB, ACE-MABTM, COVI-TRACK, COVI-STIX and COVI-TRACE are trademarks of Sorrento Therapeutics, Inc.
    ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.

COVISTAT, a Subsidiary of Ensysce Biosciences Inc, a California Based Company With a Mission to Solve the Opioid Crisis, Is Commencing Phase 1 Study of Novel COVID-19 Treatment

Retrieved on: 
Monday, September 28, 2020

Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.

Key Points: 
  • Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysces opioid overdose protection platform, is being developed as an oral treatment for COVID-19.
  • Nafamostat has a novel mechanism of action for treating COVID-19 as a potent protease inhibitor that blocks SARS-CoV-2 viral entry into host cells.
  • Because of this it has antiviral properties against other coronaviruses including the Middle East Respiratory Syndrome (MERS), SARS and now SARS-CoV-2.
  • Ensysce Biosciences is developing two new classes of opioid pain products (Trypsin Activated Abuse Protected TAAP) with overdose protection (MPAR).

Fiberlock IAQ 2500 Approved by EPA to Kill SARS-CoV-2 in 60 Seconds

Retrieved on: 
Thursday, September 24, 2020

ICP Building Solutions Group has announced its 2500 ready-to-use disinfectant has been shown to kill the novel coronavirus, SARS-CoV-2, in 60 seconds, according to new testing accepted by the U.S. Environmental Protection Agency (EPA).

Key Points: 
  • ICP Building Solutions Group has announced its 2500 ready-to-use disinfectant has been shown to kill the novel coronavirus, SARS-CoV-2, in 60 seconds, according to new testing accepted by the U.S. Environmental Protection Agency (EPA).
  • Unlike disinfectants the EPA believes will be effective against SARS-CoV-2 because they kill similar organisms, 2500 has been tested specifically against SARS-CoV-2 and has been shown to kill the virus in 60 seconds.
  • ICP intends to continue testing its other portfolio products against SARS-CoV-2 to offer customers a comprehensive solution for any application.
  • This ease of use and quick kill time make it ideal for everyday use on highly used, nonporous surfaces.